Education
About Us
Working with TipRanks
Follow Us
THNR - ETF AI Analysis
Top Page
Amplify Weight Loss Drug & Treatment ETF (THNR)
Rating:68Neutral
Price Target:―
Positive Factors
Strong Holdings Performance
Several top holdings, like Amgen and Roche, have shown strong year-to-date gains, supporting the ETF's overall performance.
Focused Sector Exposure
The ETF is heavily concentrated in the health care sector, which benefits from steady demand and innovation in treatments.
Global Diversification
The fund includes exposure to international markets like Hong Kong, Japan, and Switzerland, reducing reliance on U.S. performance alone.
Negative Factors
Underperforming Key Holdings
Some major positions, such as Novo Nordisk and Regeneron, have lagged in performance, which could drag on returns.
High Expense Ratio
The ETF charges a relatively high expense ratio compared to broader market funds, which can eat into investor returns over time.
Sector Over-Concentration
With over 93% of assets in health care, the fund is highly sensitive to risks specific to that sector.
THNR vs. SPDR S&P 500 ETF (SPY)
AUM2.85M
RegionDeveloped Markets
Expense Ratio0.59%
Beta0.70
IssuerAmplify
Inception DateMay 21, 2024
Dividend YieldN/A
Asset ClassEquity
Index TrackedVettaFi Weight Loss Drug & Treatment Index - Benchmark TR Net
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,481
30 Day Avg. Volume1,475
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
29.78Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
THNR Summary
The Amplify Weight Loss Drug & Treatment ETF (THNR) is an investment fund focused on companies in the health care sector, particularly those developing weight loss drugs and treatments. It includes well-known companies like Eli Lilly and Novo Nordisk, which are leaders in pharmaceuticals and biotechnology. This ETF could be appealing to investors looking to benefit from the growing demand for innovative health solutions and diversify their portfolio with exposure to the health care industry. However, new investors should be aware that the ETF’s performance is closely tied to the health care sector, which can be affected by regulatory changes or shifts in market demand.
How much will it cost me?The Amplify Weight Loss Drug & Treatment ETF (THNR) has an expense ratio of 0.59%, meaning you’ll pay $5.90 per year for every $1,000 invested. This is higher than average for ETFs because it is actively managed and focuses on a specialized niche in the health care sector. Actively managed funds typically have higher costs due to the research and expertise required to select investments.
What would affect this ETF?The Amplify Weight Loss Drug & Treatment ETF (THNR) could benefit from growing global awareness of obesity-related health issues and increased demand for innovative weight loss treatments, especially as its top holdings include major pharmaceutical companies like Eli Lilly and Novo Nordisk, which are leaders in this space. However, the ETF may face challenges from regulatory hurdles, competition in drug development, or economic downturns that could reduce consumer spending on health care solutions. Additionally, its heavy reliance on the health care sector makes it vulnerable to sector-specific risks, such as changes in government policies or patent expirations.
THNR Top 10 Holdings
The Amplify Weight Loss Drug & Treatment ETF (THNR) is heavily concentrated in the health care sector, with a focus on pharmaceutical and biotech giants driving innovation in weight loss treatments. Eli Lilly is a standout performer, steadily rising on the back of strong financial results and promising drug developments, while Novo Nordisk has been lagging recently due to market share challenges. Regeneron and Roche are adding momentum with robust pipelines and bullish technical signals, while AbbVie and Pfizer are holding the fund back with mixed performance and profitability concerns. Overall, the ETF’s developed markets exposure reflects a strategic bet on transformative health care advancements.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 12.88% | $367.57K | $1.02T | 35.62% | 72 Outperform | |
| Novo Nordisk | 12.44% | $355.08K | $232.25B | -40.03% | 73 Outperform | |
| Regeneron | 6.79% | $193.94K | $82.37B | 9.35% | 78 Outperform | |
| Amgen | 6.75% | $192.60K | $179.83B | 26.89% | 77 Outperform | |
| Chugai Pharmaceutical Co | 6.35% | $181.32K | ¥13.59T | 19.25% | 74 Outperform | |
| Merck & Company | 5.14% | $146.85K | $264.21B | 6.59% | 80 Outperform | |
| Roche Holding AG | 5.04% | $143.97K | CHF263.28B | 52.00% | 73 Outperform | |
| Shionogi & Co | 5.00% | $142.64K | ¥2.44T | 24.57% | 75 Outperform | |
| AbbVie | 4.95% | $141.39K | $406.30B | 28.29% | 66 Neutral | |
| AstraZeneca | 4.95% | $141.25K | $286.45B | 38.98% | 79 Outperform |
THNR Technical Analysis
Positive
―
Price Trends
24.56
Positive
23.90
Positive
22.99
Positive
Market Momentum
0.28
Negative
64.68
Neutral
88.80
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For THNR, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 25.41, equal to the 50-day MA of 24.56, and equal to the 200-day MA of 22.99, indicating a bullish trend. The MACD of 0.28 indicates Negative momentum. The RSI at 64.68 is Neutral, neither overbought nor oversold. The STOCH value of 88.80 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for THNR.
THNR Peer Comparison
Comparison Results
Performance Comparison
THNR
Amplify Weight Loss Drug & Treatment ETF
26.08
3.08
13.39%
AGNG
Global X Aging Population ETF
―
―
―
WISE
Themes Generative Artificial Intelligence ETF
―
―
―
JEDI
Defiance Drone and Modern Warfare ETF
―
―
―
ERET
iShares Environmentally Aware Real Estate ETF
―
―
―
RITA
ETFB Green SRI REITs ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents